

Malaria: progress, perils, and prospects for eradication

Brian M. Greenwood, ... , Frank H. Collins, Patrick E. Duffy

J Clin Invest. 2008;118(4):1266-1276. <https://doi.org/10.1172/JCI33996>.

Review Series

There are still approximately 500 million cases of malaria and 1 million deaths from malaria each year. Yet recently, malaria incidence has been dramatically reduced in some parts of Africa by increasing deployment of anti-mosquito measures and new artemisinin-containing treatments, prompting renewed calls for global eradication. However, treatment and mosquito control currently depend on too few compounds and thus are vulnerable to the emergence of compound-resistant parasites and mosquitoes. As discussed in this Review, new drugs, vaccines, and insecticides, as well as improved surveillance methods, are research priorities. Insights into parasite biology, human immunity, and vector behavior will guide efforts to translate parasite and mosquito genome sequences into novel interventions.

Find the latest version:

<https://jci.me/33996/pdf>





Malaria: progress, perils, and prospects for eradication

Brian M. Greenwood,¹ David A. Fidock,² Dennis E. Kyle,³ Stefan H.I. Kappe,⁴ Pedro L. Alonso,⁵ Frank H. Collins,⁶ and Patrick E. Duffy⁴

¹Department of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, London, United Kingdom.

²Department of Microbiology and Department of Medicine, Columbia University College of Physicians and Surgeons, New York, New York, USA.

³Department of Global Health, School of Public Health, University of South Florida, Tampa, Florida, USA. ⁴Malaria Program, Seattle Biomedical Research Institute, and Department of Pathobiology, University of Washington, Seattle, Washington, USA.

⁵Barcelona Center for International Health Research, University of Barcelona, Barcelona, Spain.

⁶Department of Biological Sciences, University of Notre Dame, Notre Dame, Indiana, USA.

There are still approximately 500 million cases of malaria and 1 million deaths from malaria each year. Yet recently, malaria incidence has been dramatically reduced in some parts of Africa by increasing deployment of anti-mosquito measures and new artemisinin-containing treatments, prompting renewed calls for global eradication. However, treatment and mosquito control currently depend on too few compounds and thus are vulnerable to the emergence of compound-resistant parasites and mosquitoes. As discussed in this Review, new drugs, vaccines, and insecticides, as well as improved surveillance methods, are research priorities. Insights into parasite biology, human immunity, and vector behavior will guide efforts to translate parasite and mosquito genome sequences into novel interventions.

Introduction

More than 2 billion people are at risk of malaria (1), which primarily affects poor populations in tropical and subtropical areas, where the temperature and rainfall are most suitable for the development of the malaria-causing *Plasmodium* parasites in *Anopheles* mosquitoes. Malaria once occurred widely in temperate areas, including Western Europe and the United States, but it receded with economic development and public health measures. The disease was finally eliminated in the US between 1947 and 1951 through a campaign that included household spraying of the residual insecticide dichloro-diphenyl-trichloroethane (DDT) throughout the southeastern states (2).

The Global Malaria Eradication Programme was launched by the WHO in 1955 (3) and depended on two key tools: chloroquine for treatment and prevention and DDT for vector control. Implementation of these tools had a substantial impact in some areas, particularly areas with relatively low transmission rates, such as India and Sri Lanka (3). Despite these successes, the campaign foundered in the face of lost political will and the emergence of chloroquine-resistant *Plasmodium* parasites and DDT-resistant *Anopheles* mosquitoes. Global eradication was officially abandoned as a goal in 1972 (4). Furthermore, the campaign never attempted to eradicate malaria in most parts of Africa, where malaria transmission is intense.

Since the Global Malaria Eradication Programme ended, the burden of malaria has increased substantially in many parts of the world, although in some countries (e.g., Thailand), transmission

has continued to decline in parallel with economic development, improved health infrastructure, and continued anti-vector measures (5). The resurgence of malaria was sometimes dramatic, including epidemics in Sri Lanka in 1968–1969 and in Madagascar in 1987–1988 (6). Childhood deaths in Africa due to malaria climbed relentlessly as chloroquine-resistant *Plasmodium* parasites spread across the continent (7). The rapid emergence of *Plasmodium* parasites resistant to sulfadoxine-pyrimethamine soon after this drug replaced chloroquine as first-line therapy in many parts of Africa prompted a group of leading malaria experts to warn of an impending disaster in Africa (8).

In response to this dire situation, the global community is now taking steps to deliver more effective interventions throughout Africa, including drug combinations with an artemisinin derivative and anti-vector measures. The dramatic success of these measures in a few specific areas, such as KwaZulu-Natal in South Africa (9), Eritrea (10), and the Tanzanian island of Zanzibar (11), has inspired a new call for global eradication. Achieving this ambitious goal depends on the development of new tools to treat, prevent, and monitor malaria. Further, the recent availability of genome sequences for humans, *Anopheles* mosquitoes, and *Plasmodium* parasites has raised hopes for new interventions. As this Review describes, we need a deeper understanding of parasite biology, human immunity, and vector behavior to maximally exploit genomic data for the discovery of new interventions, and these discovery efforts must be balanced against more applied research that addresses immediate priorities such as optimal implementation and protection of existing treatment and control tools.


The life cycle of *Plasmodium* parasites and targets for intervention

Among the four *Plasmodium* species that cause malaria in humans, *Plasmodium falciparum* is the most virulent. This species causes the vast majority of deaths from malaria and is also distinguished by its ability to bind to endothelium during the blood stage of the infection (Figure 1) and to sequester in organs, including the brain.

Nonstandard abbreviations used: ACT, artemisinin-based combination therapy; CSA, chondroitin sulfate A; CSP, circumsporozoite protein; DDT, dichloro-diphenyl-trichloroethane; GPI, glycosylphosphatidylinositol; IE, infected erythrocyte; IRS, indoor residual spraying; ITN, insecticide-treated bednet; PV, parasitophorous vacuole.

Conflict of interest: B.M. Greenwood, D.E. Kyle, F.H. Collins, and P.E. Duffy receive financial support for their research from the Bill and Melinda Gates Foundation. The remaining authors have declared that no conflict of interest exists.

Citation for this article: *J. Clin. Invest.* 118:1266–1276 (2008). doi:10.1172/JCI33996.

**Figure 1**

The life cycle of malaria-causing *Plasmodium* parasites. The *Plasmodium* life cycle comprises numerous transitions and stages, and any of these can be targeted by host immune responses. Upon inoculation by an *Anopheles* mosquito into the human dermis, elongated motile sporozoites must evade antibodies to (i) access blood vessels in the skin and then (ii) transit through liver macrophages and hepatocytes to initiate liver stage infection. Intrahepatocytic parasites (iii) are susceptible to CTLs. After approximately one week, infected hepatocytes rupture and release merozoites as aggregates called merosomes that might allow merozoites to (iv) evade antibodies and invade erythrocytes. Intraerythrocytic parasites (v) are susceptible to opsonizing antibodies and macrophages, and cytokine responses have been related to both protection and disease during this stage of infection. Antibodies that block (vi) binding of *P. falciparum*-infected erythrocytes to endothelium might prevent disease and control parasitemia. Human antibodies specific for (vii) sexual stage parasites are taken up by mosquitoes during the blood meal and can block transmission to mosquitoes, although these might require complement for parasite killing. *Anopheles* mosquito innate immune responses can also kill parasites during early (vii) or late (viii) sporogonic stages and lead to refractoriness to infection.



Potential end points for assessing the impact of an anti-malarial intervention

Nonpregnant adults and children^A

- All causes of mortality
- Malaria-specific mortality
- Hospital admissions with severe malaria
- Laboratory-confirmed clinical attacks of malaria
- Prevalence of malaria parasitemia in the community
- Prevalence of anemia in the community

Pregnant women

- Maternal mortality
- Prevalence of anemia
- Incidence of low birth weight

Vector mosquitoes

- Numbers
- Infection rate

^AIn highly endemic areas, the main burden of malaria is in children, and most surveys focus on this age group.

Plasmodium vivax is less deadly but highly disabling; it is common in tropical areas outside Africa (most Africans lack the Duffy blood group antigen that is expressed on the surface of erythrocytes and is a necessary receptor for *P. vivax* invasion of these cells). The ability of *P. vivax* and also *Plasmodium ovale* to remain dormant for months as hypnozoites in the liver makes infection with these parasites difficult to eradicate. *Plasmodium malariae* does not form hypnozoites, but it can persist for decades as an asymptomatic blood stage infection. A fifth species, *Plasmodium knowlesi*, which was originally described as a malaria parasite of long-tailed macaque monkeys, also naturally infects humans in some areas, such as Malaysia (12).

Infection of the human host with a *Plasmodium* parasite begins with the bite of an infected *Anopheles* mosquito that inoculates the individual with sporozoites (Figure 1). These motile forms of the parasite rapidly access the blood stream and then the liver, where they invade hepatocytes. The asymptomatic liver stage of infection lasts about 6 days, with each sporozoite yielding tens of thousands of merozoites that then invade and develop within erythrocytes. The blood stages of infection include asexual forms of the parasite that undergo repeated cycles of multiplication as well as male and female sexual forms, called gametocytes, that await ingestion by mosquitoes before developing further. Asexual blood stage parasites produce 8–20 new merozoites every 48 hours (or 72 hours for *P. malariae*), causing parasite numbers to rise rapidly to levels as high as 10¹³ per host. The asexual stages are pathogenic, and infected individuals can present with diverse sequelae affecting different organ systems. Sexual stage parasites are nonpathogenic but are transmissible to the *Anopheles* vector, where they recombine during a brief period of diploidy and generate genetically distinct sporozoites (13). The mosquito becomes infectious to its next blood meal donor approximately two weeks after ingesting gametocytes, a time frame that is influenced by the external temperature. Development of *P. vivax* within the mosquito can occur at a lower environmental temperature than that required for the development of *P. falciparum*, explaining the preponderance of *P. vivax* infections outside tropical and subtropical regions.

During its peripatetic existence, the unicellular malaria-causing parasite uses a toolkit of more than 5,000 genes (14) to undergo dramatic metamorphoses that are suited to the numerous environments and barriers it encounters. These changes include the development, at different points in its life cycle, of motile, invasive, encysted, intracellular, sexual, and dormant forms. These distinct forms of the parasite help enable it to complete its full life cycle (Figure 1), during which it must pass through the mosquito midgut and salivary glands; localize and penetrate skin vessels; perforate and traverse macrophages and several hepatocytes prior to enveloping itself in an intrahepatocytic vacuole; and attach to and reorient itself on the surface of erythrocytes prior to invasion.

Each of the developmental stages discussed above represents a potential target at which the life cycle can be interrupted. Vaccines, drugs, and anti-vector measures are being developed to prevent infection, disease, and transmission. Despite numerous potential targets, the most widely used old compound (quinine, isolated from cinchona bark in 1820) and the best new compound (artemisinin, purified from *Artemisia annua* in 1972) for treatment are both derived from ancient herbal therapies. Further, progress with developing a vaccine is incomplete. These limitations stem, in part, from the fact that since its discovery in 1880 (15), the parasite has been slow to reveal its secrets, including its metabolic pathways and its antigens that are targeted by protective immunity. However, recent advances in determining the genome sequences for humans, *Anopheles* mosquitoes, and *Plasmodium* parasites have raised hopes that developing new interventions might be feasible.

Epidemiology and clinical features

Global disease burden and surveillance. Efforts to control malaria are being made on a scale not seen for fifty years. However, the long-term sustainability of this effort depends on demonstrating a beneficial impact on health and development. This requires that the distribution and burden of malaria be determined before and after the initiation of interventions — data that are hard to collect. Indeed, most malaria-endemic countries, particularly those in sub-Saharan Africa, have weak health information systems and civil registries, and the consequences of a malaria infection are varied, meaning that many indicators are used to measure the impact of an intervention (see *Potential end points for assessing the impact of an antimalarial intervention*). Malaria is such a common cause of childhood death that successful interventions are likely to have a discernible impact on the overall childhood mortality rate in endemic areas. Overall mortality can be measured either through indirect demographic techniques or directly in sites with continuous demographic surveillance systems. In contrast, malaria-specific mortality is much more difficult to document because most deaths from malaria occur at home. Malaria morbidity requires either the use of health facilities as sentinel sites or regularly conducted community-based surveys.

Despite the difficulties, considerable progress has been made in defining the global distribution of malaria (16, 17) and its burden. Because the clinical diagnosis of malaria is imprecise, estimates of the burden of malaria that rely upon clinical data without laboratory support are unreliable. However, improved regional and global estimates of the malaria burden have used accurate data collected at a limited number of areas with well-defined geographical, entomological, and population characteristics, which are then extrapolated to other areas with similar characteristics and known populations. Studies of this kind suggest that malaria directly



causes just under 1 million deaths and at least 500 million clinical cases each year (1, 18). Furthermore, malaria in pregnancy contributes to a substantial number of maternal deaths as well as infant deaths resulting from low birth weight (19).

Transmission of malaria-causing parasites is typically infrequent but also unstable (i.e., transmission varies in prevalence and is prone to change) in substantial areas of Southeast Asia and South America and might become more unstable in Africa as disease control improves. Because levels of immunity are also low, areas of unstable transmission are prone to epidemics, during which mortality and morbidity can be very high. Research that improves the prediction of epidemics is therefore critical. Climate modeling can give long-range warnings of heavy rainfalls, and hence of increased mosquito breeding and risk of malaria (20). Active surveillance at district health centers can detect an early increase in cases and allow appropriate control measures to be put in place before a large epidemic explodes (21). As malaria control improves, surveillance will become necessary to identify persistent and new foci of infection as well as localized areas where control measures are not working. Sensitive PCR techniques for detecting asexual (22) and sexual stage infections (23) as well as new serological methods (24) might be helpful at this stage of malaria control.

Diagnosis and clinical spectrum of disease. Clinical diagnosis of malaria is difficult, and misdiagnosis is frequent when laboratory confirmation is not available or is disregarded by doctors anxious to identify a treatable cause of illness. Microscopy remains an important tool for diagnosis, but laboratory diagnosis in clinics without microscopy has now become possible through the development of rapid diagnostic tests (25). Some tests, however, deteriorate under tropical conditions and can give false results (26). Furthermore, health care staff might still overtreat for malaria even when rapid tests are available (27), possibly because they lack facilities to identify other causes of fever and because malaria symptoms overlap with those of many illnesses. Finding ways to change the attitudes of health care providers and the perceptions of patients as to what they should receive at the clinic is an important applied research priority.

Uncomplicated malaria usually presents with fever and nonspecific symptoms, such as vomiting and/or diarrhea, a clinical picture that resembles that of many other childhood infectious diseases. In adults, severe malaria caused by *P. falciparum* is characterized by multiorgan damage, including renal failure. This is uncommon in children with severe malaria, who usually present with prostration, respiratory distress, severe anemia, and/or cerebral malaria. Each of these clinical presentations of malaria probably represents a complex of conditions, each with their individual pathogenesis, complicating the effort to develop broadly effective adjunctive therapies. Additional abnormalities, such as hypoglycemia and acidosis, can complicate and/or contribute to severe malaria.

What determines the pattern of severe malaria in an individual case is not fully understood. Genetic factors are important (28), and both the age of the patient and the intensity of transmission in the community influence susceptibility to cerebral malaria and severe anemia (29). Cerebral malaria is a more common presentation of severe malaria where transmission intensity is low, whereas severe anemia predominates where transmission intensity is high. Retinal changes occur in many patients with severe malaria, and a specific pathology was recently described that might aid diagnosis (30). Children with severe malaria rarely present with the classical features of circulatory shock, but recent studies have suggested,

controversially, that many have hypovolemia that contributes to their acidosis (31, 32).

Malaria can interact with other infectious diseases to modify the susceptibility and/or severity of either disease. For example, solid evidence now indicates that infection with HIV increases the risk of uncomplicated and severe malaria (33). Conversely, malaria causes a transitory increase in viral load (34), and this could promote HIV transmission. In pregnant women, malaria and infection with HIV interact to cause low birth weight, and HIV impairs the efficacy of drugs used for malaria prevention (35). Coinfection with helminths seems to protect against severe malaria in some, but not all, areas, which might indicate that the interaction is site specific and determined by local patterns of malaria and helminth infections (36, 37). Finally, a marked percentage of African children with severe malaria are increasingly recognized to have associated bacteremia, and these patients might have increased mortality (38). Infection with nontyphoidal *Salmonella* spp. is an important complication of severe malaria anemia, but the mechanism of this association is not understood (39).

Parasite biology, drugs, and resistance

The discovery of new agents to prevent or treat malaria has benefited from the sequencing of the parasite genome (14) and the development of improved tools for functional genomics (40–43), yet this area of research remains limited by our incomplete knowledge of parasite biology. In the case of the asexual blood stage parasites, research has identified several processes, such as hemoglobin degradation and heme detoxification, folate biosynthesis, and protein synthesis in the apicoplast, as effective targets for therapeutic intervention (44). An expansion of this research effort is critical to defining the pathways that are most suitable for intervention, to validating candidate drug targets (Figure 2), and to identifying chemically tractable inhibitors for drug development. The discovery of drugs targeting either liver or sexual stage parasites faces even greater gaps in knowledge. For example, the only drugs that target liver stage parasites are the long-ago-discovered 8-aminoquinolines (such as primaquine and tafenoquine, whose modes of action are unknown) or are the products of discovery efforts for asexual blood stage parasites (such as atovaquone, an inhibitor of the mitochondrial cytochrome *bc1* complex that is part of the electron transport chain in this organelle) (45, 46). Why are drugs with activity against asexual blood stage parasites so often ineffective against liver stage parasites, and which biochemical pathways constitute the best targets for developing drugs with activity against liver stage parasites? Recent advances in visualizing the sporozoite invasion process and the discovery of merozoites might soon reveal new targets for drug and vaccine discovery (47–49). However, only a few laboratories are able to produce liver stage forms of human parasites because of the technical restrictions of establishing the specialized insectariums required to produce infectious sporozoites in *Anopheles* mosquitoes and the difficulties of generating large numbers of sporozoite-infected hepatocytes either in vitro or in vivo. Progress in this important area has therefore been slow. New drugs are urgently needed to target *P. vivax* liver stage parasites, including the dormant hypnozoite forms that can cause relapses, yet no in vitro methods exist to guide the drug discovery and development processes. Only an adequate investment in basic biological investigations of the *Plasmodium* life cycle, focusing on *P. falciparum* and *P. vivax*, can provide the knowledge needed to identify new targets and strategies for prophylaxis or treatment.




Figure 2

Antimalarial drugs mediate their effects by disrupting processes or metabolic pathways in different subcellular organelles. The 4-aminoquinolines, including chloroquine and amodiaquine, and the quinolinemethanols, including quinine and mefloquine, concentrate inside the acidic digestive vacuole, where they are believed to bind β -hematin and interfere with heme detoxification. The falcipain inhibitors that are under development target cysteine proteases that participate in hemoglobin degradation in this digestive vacuole. Antibiotics such as azithromycin, doxycycline, and clindamycin act inside the chloroplast-like plastid organelle, where they inhibit protein translation, resulting in the death of the progeny of drug-treated parasites (the “delayed-death” phenotype). Atovaquone and select other compounds inhibit electron transport in the mitochondrion, whereas antifolates disrupt de novo biosynthesis of folate in the cytosol. Only drugs for which the site of action is known with confidence are assigned to a subcellular location. Indeed, the targets and sites of action of other antimalarials, including artemisinin and artemisinin derivatives, remain an area of active investigation. Reproduced with permission from Nature Publishing Group (44).

To adequately treat malaria, drugs must be fast acting, highly potent against asexual blood stage infections, minimally toxic, and affordable to residents of endemic regions. Drugs are also used to control malaria. For example, intermittent presumptive treatment (IPT) with sulfadoxine-pyrimethamine during second and third trimesters improves pregnancy outcomes (50) and is recommended as part of routine antenatal care throughout Africa. IPT strategies might also benefit infants (51, 52). The spread of *P. falciparum* resistant to the former first-line antimalarials chloroquine and sulfadoxine-pyrimethamine (53–55) has had a devastating impact on malaria treatment and control and has spurred multiple investigations into the development of new antimalarials, with an emphasis on artemisinin-based combination therapies (ACTs) (56, 57). ACTs combine a derivative of the natural product artemisinin, an extremely potent and fast-acting antimalarial endoperoxide, with a longer-lasting partner drug that continues to reduce the parasite biomass after the short-lived artemisinin has dropped below therapeutic levels. Artemisinin derivatives act rapidly against asexual blood stage parasites to alleviate symptoms and have the additional beneficial effect of killing gametocytes and therefore decreasing parasite transmission. Distinct modes of action of artemisinins and partner drugs should, in theory, enable the combination to kill parasites that manifest decreased susceptibility to one agent. Clinical studies in Thailand

have shown excellent efficacy with the ACT mefloquine-artesunate, despite the relatively facile acquisition of parasite resistance to mefloquine (58). Mefloquine, however, is comparatively expensive and presents toxicity concerns. Current efforts are therefore focused on evaluating the impact of other ACTs, including artemether-lumefantrine, dihydroartemisinin-piperazine, and artesunate-amodiaquine, when they are deployed as new first-line treatments. Most countries in the world have now switched to an official policy of using an ACT as the first-line treatment.

Will a worldwide switch to ACTs substantially and sustainably reduce the global burden of malaria? We would argue a qualified yes. The potency and clinical efficacy of ACTs, as well as the lack of proven cases of artemisinin treatment failure after ACT therapy until recently, attest to the promise of these drug combinations to dramatically reduce malaria. This occurred in KwaZulu-Natal where indoor residual spraying (IRS), active case detection, and deployment of artemether-lumefantrine in 2001 rapidly reversed an epidemic (9). Achieving similar results in other African nations, which unlike South Africa suffer from inadequate infrastructure and high transmission rates, is uncertain and will require sustained investments in health care delivery as well as subsidies for new drugs and other measures. Recent evidence that a similar impact can be achieved comes from a study in Zanzibar (8), which



reported a dramatic reduction in the rates of malaria-associated morbidity and mortality within two years of administering either artesunate-amodiaquine or artemether-lumefantrine free of charge to patients with malaria presenting at public health facilities (11). The subsequent combination of treatment with ACTs and distribution of insecticide-treated bednets (ITNs) produced a 10-fold reduction in the prevalence of parasitemia within a year.

Yet substantial concerns about ACTs remain. First, will repeated use of artemisinin derivatives cause toxicities similar to those observed in animal models (59, 60)? For example, brainstem neurotoxicity with chromatolysis has been observed in rats after high and repeated parenteral doses of artemisinins; and dihydroartemisinin-induced damage to primitive erythrocytes during yolk sac hematopoiesis as well as embryonic abnormalities and resorptions occurred in rats if the drug was administered during a short window of time after conception. This issue requires a detailed analysis, particularly in children and pregnant women – the individuals that get malaria and malaria treatments most frequently. Second, will resistance (inevitably) arise, and how can this be delayed? In vivo resistance to artemisinin and artemisinin derivatives has been selected in a *P. chabaudi* rodent malaria line that was repeatedly passaged in the presence of increasing concentrations of either artemisinin or artesunate (61). This result illustrates that resistance can occur in *Plasmodium* parasites and was obtained in a genetically tractable model that can be used to define resistance determinants.

Clinical data have revealed that ACT clinical failure can result from parasite resistance to the partner drug, and amplification of the *pfmdr1* gene has been identified as a key determinant of resistance to mefloquine and lumefantrine in Southeast Asian strains of *P. falciparum* (62, 63). This amplification is believed to result in overexpression of the PfMDR1 transporter, located on the membrane of the digestive vacuole within which hemoglobin degradation and heme detoxification occur. PfMDR1 overexpression might confer resistance by sequestering the drug away from its site of action. This mechanism does not seem to account generally for instances of resistance to mefloquine and lumefantrine in African strains of *P. falciparum* (64). Laboratory studies are urgently required to decipher determinants of resistance to ACT drugs in geographically distinct parasite strains. This should identify the drugs that are least prone to resistance and yield molecular markers that can serve as resistance sentinels. Mode-of-action studies are also essential to create a biological rationale for choosing new ACTs that have complementary and, ideally, synergistic activities and that will not readily fall prey to existing or newly acquired resistance mechanisms. In addition, pharmacokinetic/pharmacodynamic studies are required to optimize treatment regimes and doses and minimize recrudescence or selection for resistant parasites. Finally, discovery and development of new antimalarial drugs, separate from the artemisinins, must proceed so that replacements will be ready if and when ACTs reach the end of their clinical life.

Pathogenesis, immunity, and vaccines

Biology of pre-erythrocytic sporozoites and liver stage parasites. *Plasmodium* parasites encounter numerous anatomic barriers during their life cycle, and immune responses can interrupt parasite development either by blocking these key transitions or by directly killing the pathogen (Figure 1). Pre-erythrocytic sporozoites and liver stage parasites are very attractive targets for vaccines that aim to completely prevent infection (65–67). The advantage of targeting these forms of the parasite is that there are only small numbers to eliminate (68);

at most, a few dozen sporozoites are transmitted during mosquito blood feeding and infect the liver. The pre-erythrocytic stages of the life cycle are completely asymptomatic and provide a relatively large window of opportunity for an effective immune response to eliminate the parasite (approximately 6 days for *P. falciparum*). Unfortunately, pre-erythrocytic infection in humans is experimentally intractable for practical purposes and consequently has remained poorly understood. In contrast, the pre-erythrocytic stages of disease in rodent models of malaria are amenable to direct experimental interrogation. Within the past few years, intravital imaging, gene knockouts, and other approaches have contributed to a cellular and molecular understanding of the initial stages of sporozoite transmission, liver infection, and liver stage development. Many of these findings have important implications for vaccine development.

When an infected *Anopheles* mosquito seeks a blood meal, it engages in repeated probing, each time releasing saliva and sporozoites into the dermal and subdermal tissue of the host (69). Sporozoites migrate through the skin to make contact with a blood vessel, then traverse the endothelium to enter the blood stream (49, 69). This skin phase of infection is highly susceptible to neutralization by antibodies that bind sporozoite surface proteins, mainly the circumsporozoite protein (CSP), effectively immobilizing the parasite (69). However, sporozoites sometimes gain immediate access to the blood stream, when mosquitoes directly cannulate a blood vessel. Sporozoites are then carried to the liver, entering the sinusoids through the portal fields. Sinusoids exhibit a highly specialized endothelium consisting mainly of fenestrated endothelial cells and stationary macrophages called Kupffer cells.

Sporozoites attach to the endothelial lining of liver sinusoids by interactions of their surface proteins (CSP and thrombospondin-related anonymous protein [TRAP]) with host extracellular matrix proteoglycans (70). CSP and TRAP are also crucial for sporozoite motility and infection of host cells (71). Sporozoites glide along the endothelium, then penetrate and traverse Kupffer cells to gain access to hepatocytes (72). Cell traversal seems to depend on at least two sporozoite secretory proteins, one of which contains a perforin-like membrane insertion domain that might allow the sporozoite to breach the cell membrane (73, 74). Importantly, sporozoites suppress the respiratory burst in Kupffer cells (75) and inhibit antigen presentation and cytokine release, which in turn might weaken an effective immune response against the parasite (76). Sporozoites can subsequently pass through a number of hepatocytes, which die by necrosis, before settling in a hepatocyte for further liver stage development (Figure 1) (77).

Liver stage development requires the formation of a specialized membrane compartment, called the parasitophorous vacuole (PV), in which the parasite is shielded from the host cell cytoplasm (78). Initial PV formation depends on secretory proteins that are characterized by 6-cysteine domains; sporozoites lacking 6-cysteine proteins enter hepatocytes but cannot form a PV (79) and do not undergo subsequent liver stage development. Additional proteins that the parasite inserts into the PV membrane might facilitate nutrient uptake from the host cell, as has been suggested for the UIS3 protein (80). Parasites lacking these PV proteins stop growing early in infection (81–83). 6-Cysteine protein-deficient (79) and PV protein-deficient parasites are thus effectively attenuated and cannot initiate blood stage infection (81–83).

Vaccines against pre-erythrocytic parasites. Parasites lacking either a 6-cysteine protein or a PV protein are live attenuated parasites that are powerful vaccines and build on groundbreaking work in the



1960s and 1970s that showed sterile, long-lasting protection in mice (84) and humans (85) after vaccination with radiation-attenuated sporozoites. In mice, single-dose immunization with specific genetically attenuated parasites can induce complete protection against subsequent sporozoite infection, and prime-boost immunizations induce protection for at least 6 months (83). Protection is, to some extent, mediated by antibodies that prevent sporozoite invasion of hepatocytes. CD8⁺ T cells, however, are crucial and eliminate the remaining infected hepatocytes through both direct cytotoxicity and IFN-mediated mechanisms (83, 86, 87) similar to their role in protection induced by radiation-attenuated parasites (88). Efforts are underway to test *P. falciparum* parasites attenuated by deletion of the essential 6-cysteine proteins P52 and P36 (79), the essential PV membrane protein UIS3 (82), and the essential PV membrane protein UIS4 (81), as vaccines in humans (www.sbri.org). A separate effort seeks to develop the logistical means to deliver a radiation-attenuated vaccine (www.sanaria.com), and these delivery approaches could equally be applied to a genetically attenuated parasite.

Subunit vaccines have achieved lower efficacy than whole-parasite vaccines in phase IIa clinical trials (89, 90) but are logistically simpler. After a long history of disappointing results with other candidates, one subunit vaccine called RTS,S has shown promise in phase IIb clinical trials (91–94). RTS,S incorporates a fusion protein — which comprises CSP and the HBV surface antigen and aggregates as virus-like particles — and the adjuvant AS02, which is based on monophosphoryl lipid A and QS-21 (89). Vaccination with 3 doses of RTS,S prevented infection in 41% of malaria-naive adult volunteers in the US when they were challenged with sporozoites delivered by mosquito bite (90). In The Gambia, vaccination of adults naturally exposed to malaria-causing parasites with 3 doses of RTS,S achieved 74% efficacy in delaying the appearance of parasitemia during the first 9 weeks following vaccination, but this efficacy waned to 0% by the end of the transmission season; a booster dose the following season provided 47% efficacy during the first 9 weeks (91).

In Mozambique, 3 doses of RTS,S/AS02A given at monthly intervals to infants (93) and to children age 1–4 years (94) reduced the risk of infection with *P. falciparum*. Unlike in the studies in adults in The Gambia, the benefits in children seemed to be sustained for more than a year, with an overall vaccine efficacy of 35.3% against clinical malaria and 48.6% against severe malaria during 18.5 months of observation after the third dose of vaccine. These encouraging results have prompted plans for a large, multicenter trial that might lead to licensure of the product. The demonstration that the vaccine retains its efficacy when the AS02 adjuvant is lyophilized and reconstituted at the time of immunization, rather than coformulated at the time of manufacture, might simplify the logistics of delivering the vaccine (95). The results are also stimulating the search for additional pre-erythrocytic antigens that improve upon this success, either in combination with the CSP antigen or alone.

Immunity and vaccines against blood stage parasites. Vaccines against pre-erythrocytic stage parasites, such as RTS,S, have been designed to prevent infection and thereby prevent disease. Vaccines against the pathogenic asexual blood stages also have a strong rationale, but their primary goal is to prevent disease and not infection. Immunity to blood stage parasites is naturally acquired, limits parasitemia, and prevents disease; it is passively transferred to children in the IgG fraction of immune serum (96). Furthermore, immunity that prevents severe malaria is acquired rapidly, perhaps after only one or two episodes of severe disease (97), suggesting that the target antigens have limited diversity.

Liver stage development is a single cycle for the parasite, whereas asexual blood stage development is a repeating cycle, each cycle terminating with the release of a new brood of merozoites that invade fresh erythrocytes in only a few seconds. The ability of the merozoite to specifically attach to and invade erythrocytes is essential for blood stage development; for example, *P. vivax* must bind to the Duffy antigen to invade reticulocytes (98). This and other findings have inspired the search for merozoite antigens that elicit antibodies that block parasite invasion of erythrocytes. However, none of the merozoite antigens that have been tested in humans, including merozoite surface protein-1 and apical merozoite antigen-1, have yet been shown convincingly to confer high levels of protection. The Duffy antigen-binding protein of *P. vivax* is soon to be tested as a vaccine in humans, to determine whether antibodies blocking this essential receptor-ligand interaction can confer protection (99). Unlike *P. vivax*, *P. falciparum* uses multiple redundant pathways to invade erythrocytes, complicating the effort to develop anti-invasion vaccines against the latter (100).

Blood stage immunity might also target parasite proteins that are variably expressed on the surface of infected erythrocytes (IEs). These proteins are exported by intraerythrocytic parasites for specialized functions such as adhesion to endothelium and immunoevasion. The best example of this has been demonstrated during pregnancy. In women who are pregnant, *P. falciparum* parasites emerge that express distinct IE surface proteins, allowing these IEs to bind chondroitin sulfate A (CSA) and sequester in the placenta (101). First-time mothers lack antibodies specific for the IE surface proteins of these parasites and are highly susceptible to infection and disease (102). Women become resistant over successive pregnancies as they acquire antibodies that block IE binding to CSA (102). Placental parasites express distinct genes and proteins (103), including an IE variant surface protein called VAR2CSA (104) that is required for adhesion to CSA in some parasite lines (105) and that binds CSA in vitro (106). A program to develop a vaccine based on VAR2CSA or the other proteins expressed by placental parasites is well under way (107).

Preventing malaria in pregnant women offers a paradigm for vaccines that prevent specific syndromes by blocking sequestration of distinct parasite forms. An alternative vaccine model targets parasite toxins that can cause inflammatory responses and severe sequelae; that is, the vaccines target not the parasite causing the infection but the mediators of disease. The febrile paroxysms of malaria occur as merozoites are released from IEs, and the glycosylphosphatidylinositol (GPI) tail that is common to several merozoite surface proteins has been implicated as a key parasite toxin (108). Unlike host GPIs, parasite GPIs contain palmitic or myristic acids at C-2 of inositol and lack phosphoethanolamine substitution in core glycan structures (109). Vaccination with parasite GPI induces protection from disease in animal models (110), and antibodies specific for parasite GPI (mainly for the acylated phosphoinositol portion) are naturally acquired by humans in endemic areas; this is related to improved outcomes in some, but not all, studies (109, 111, 112).

Vaccination against sexual stage parasites. Vaccines against the sexual stages of the malaria parasite life cycle have been successful at preventing parasite transmission in experimental animals (113) and are being pursued as approaches to prevent transmission of both *P. falciparum* and *P. vivax*. Such vaccines will not provide any immediate direct benefit to the vaccinated individual, but their widespread deployment will help to reduce transmission of the para-



site and thus protect both the vaccinated individual and his/her community. Vaccines that block parasite transmission are likely to be used in combination with vaccines targeting other stages of the infection and might prevent the transmission of parasite escape mutants that arise to evade protective immune responses. When used in combination with vector control measures described below, vaccines that block transmission could play a key role in finally breaking the transmission of malaria-causing parasites, leading to eradication of the disease.

Vector biology and control

The intensity and pattern of transmission of malaria-causing parasites, and therefore the epidemiology of infection and disease, are largely a function of the seasonality, abundance, and feeding habits of the *Anopheles* mosquito vector. Where malaria elimination programs have been successful, such as those implemented in the US and Europe, vector control was an essential program component. Contemporary vector control strategies include ITNs, long-lasting ITNs (LLINs), and IRS. IRS with DDT was an essential component of the Global Malaria Eradication Programme in the past century and remains highly effective in regions where mosquitoes are sensitive to the insecticide, such as KwaZulu-Natal (9). ITNs have been shown to increase child survival substantially in studies at several sites across Africa (114–116). Current priorities for research on vectors include studies to sustain and/or enhance the effectiveness of existing methods, as well as efforts to develop novel strategies for vector-targeted malaria control.

Research to sustain current control methods. Resistance to pyrethroid insecticides is one of the most pressing research problems for vector biologists. Only pyrethroid insecticides are licensed for use in ITNs. Therefore, tools to rapidly detect the many genetic mechanisms that can underlie pyrethroid resistance are urgently needed. These insecticides act by binding to a voltage-gated sodium channel responsible for neuronal signal transmission. Unfortunately, pyrethroid resistance has appeared in many vector populations, particularly in Africa. Despite an insecticide program, vector populations rebounded in southern Mozambique when *Anopheles funestus* resistant to pyrethroid emerged in 1999 (117–119). More recently, pyrethroid resistance in *Anopheles gambiae* has been associated with program failure in Benin (120). Beyond these two clear examples, insecticide resistance has been detected in many other vector populations but not yet linked to any loss of effectiveness in malaria control programs (121, 122).

In this context, strategies are desperately needed to maximize the longevity of the pyrethroid insecticides used for ITNs and to develop and/or license new insecticides for malaria control. IRS strategies, although potentially more costly and difficult to implement than ITN and LLIN programs, have the advantage that they can be based on a broader group of licensed insecticides, including the well-known and cost-effective pesticide DDT. Unfortunately, DDT and pyrethroid insecticides target the same voltage-gated sodium channel protein. Furthermore, a set of mutations that alters protein structure and confers resistance to DDT also confers resistance to pyrethroids (123). Fortunately, not all forms of resistance to DDT and pyrethroid insecticides cross-react, and thus these two widely effective types of insecticides can often supplement or replace each other. However, the development of new insecticides with active compounds that have different target sites is a priority research area for malaria control.

Given the central place of DDT and pyrethroid insecticides in malaria control today, these two insecticides must be used judiciously. Because IRS programs put much larger amounts of insecticide into the environment than ITN programs, they effectively subject the vector population to higher levels of selection for resistance. For this reason, we believe that pyrethroids should not be used for IRS programs. Another insecticide, such as DDT or one that does not target the same voltage-gated sodium channel as DDT and pyrethroids, should be deployed for IRS programs, preserving pyrethroids for use in ITNs.

Development of new, vector-targeted malaria control strategies. New and improved strategies for malaria control are also motivating research on malaria vectors. One approach that offers the potential for near-term results is focused on the molecular and biochemical mechanisms that underlie key vector behaviors, for example, blood meal host selection (124, 125). Molecular pathways such as those involving the odorant receptors used in host finding and blood feeding are being studied as potential targets of novel, species-specific attractants and repellents. Another approach uses genetic manipulation to modify the ability of the natural vector population to transmit the pathogen. Exciting progress has been made in the investigation of genes encoding potential effector proteins that can interrupt parasite development in the mosquito (126, 127), as well as strategies to drive such genes into natural populations (128, 129).

Broad-based analyses of the genomes of vectors (130, 131) and pathogens, and the use of these new genomic data to better understand the complex population structure of natural vector populations, hold the key to long-term solutions. Ultimately, these kinds of research activities will not only advance new control ideas currently being contemplated but will also be the source of new approaches not yet recognized.

Conclusion

Over half a century ago, the development of chloroquine and DDT inspired an international campaign to eradicate malaria that made substantial progress in many areas, especially outside Africa. However, political and financial commitments waned, in parallel with the emergence and spread of chloroquine-resistant *Plasmodium* parasites and DDT-resistant *Anopheles* mosquitoes. A global resurgence of malaria ensued, including in areas where it had been largely eliminated.

Today, we are witnessing a redoubling of efforts and resources to attack the malaria problem, and this time the emphasis is on Africa, where the burden of malaria is greatest. As malaria comes under control in highly endemic areas, the pattern of infection and disease will change, with an increasing proportion of cases occurring in older children and adults and with an increased risk of local outbreaks. The latter will be especially likely to occur if control measures are allowed to lapse in the face of a decreasing burden of infection. Extensive surveillance will therefore be required to monitor these changes and to define optimal and cost-effective strategies for managing pre-elimination situation.

Meanwhile, resources for malaria research efforts remain meager, and the international community continues to face difficult decisions on how to balance efforts in discovery, development, and implementation of new tools. The emergence of artemisinin resistance is one of the greatest threats to renewed efforts to eradicate malaria, and reports from the Thai-Cambodian border are raising concerns that this might already be occurring (132).



Although current tools make it possible to quickly identify the genetic basis of drug resistance, do we have sufficient knowledge, tools, and multinational cooperation to effectively prevent the spread of resistant parasites?

Experience indicates that the most effective control programs are those that apply a combination of tools and that the efficacy of current interventions will one day be lost to a changing parasite or mosquito. Furthermore, our existing interventions are insufficient to meet the ambitious goal of global eradication. New concepts and tools are required to achieve eradication, hence the impetus to explore transmission-blocking and live attenuated parasite vaccines as well as anti-vector measures targeting novel processes. The *Plasmodium* parasite and its *Anopheles* vector offer many targets for intervention, and we have only just begun to harvest their genome sequences for insights into new interventions and a deeper understanding of host-parasite interactions. The future of malaria control and eradication efforts hinges on how well the scientific and public health communities can work together to

extend the effective life span of our existing tools while discerning new interventions that interrupt the complex life cycle of *Plasmodium* parasites.

Acknowledgments

S. Mikolajczak helped develop the design for Figure 1. The authors receive financial support for their research from the Bill and Melinda Gates Foundation (B.M. Greenwood, D.E. Kyle, F.H. Collins, P.E. Duffy), the Burroughs Wellcome Fund (D.A. Fidock), the Foundation for NIH/Grand Challenges in Global Health (S.H.I. Kappe, P.E. Duffy), the Malaria Vaccine Initiative at PATH (P.L. Alonso, P.E. Duffy), and the NIH (D.A. Fidock, D.E. Kyle, S.H.I. Kappe, F.H. Collins, P.E. Duffy).

Address correspondence to: Patrick E. Duffy, Seattle Biomedical Research Institute, 307 Westlake Avenue North, Suite 500, Seattle, Washington 98109, USA. Phone: (206) 256-7311; Fax: (206) 256-7229; E-mail: Patrick.Duffy@sbri.org.

1. Snow, R.W., Guerra, C.A., Noor, A.M., Myint, H.Y., and Hay, S.I. 2005. The global distribution of clinical episodes of *Plasmodium falciparum* malaria. *Nature*. **434**:214–217.
2. Zucker, J.R. 1996. Changing patterns of autochthonous malaria transmission in the United States: a review of recent outbreaks. *Emerg. Infect. Dis.* **2**:37–43.
3. WHO. 1999. Making a difference. The World Health Report 1999. *Health Millions*. **25**:3–5.
4. Brito, I. 2001. Eradicating malaria: high hopes or a tangle? *Health Policy at Harvard*. **2**:61–66.
5. Chareonviriyaphap, T., Bangs, M.J., and Ratanatham, S. 2000. Status of malaria in Thailand. *Southeast Asian J. Trop. Med. Public Health*. **31**:225–237.
6. Roberts, D.R., Manguin, S., and Mouchet, J. 2000. DDT house spraying and re-emerging malaria. *Lancet*. **356**:330–332.
7. Snow, R.W., Trape, J.F., and Marsh, K. 2001. The past, present and future of childhood malaria mortality in Africa. *Trends Parasitol.* **17**:593–597.
8. White, N.J., et al. 1999. Averting a malaria disaster. *Lancet*. **353**:1965–1967.
9. Barnes, K.I., et al. 2005. Effect of artemether-lumefantrine policy and improved vector control on malaria burden in KwaZulu-Natal, South Africa. *PLoS Med.* **2**:e330.
10. Nyarango, P.M., et al. 2006. A steep decline of malaria morbidity and mortality trends in Eritrea between 2000 and 2004: the effect of combination of control methods. *Malar. J.* **5**:33.
11. Bhattarai, A., et al. 2007. Impact of artemisinin-based combination therapy and insecticide-treated nets on malaria burden in Zanzibar. *PLoS Med.* **4**:e309.
12. Singh, B., et al. 2004. A large focus of naturally acquired *Plasmodium knowlesi* infections in human beings. *Lancet*. **363**:1017–1024.
13. Aravind, L., Iyer, L.M., Wellem, T.E., and Miller, L.H. 2003. *Plasmodium* biology: genomic gleanings. *Cell*. **115**:771–785.
14. Gardner, M.J., et al. 2002. Genome sequence of the human malaria parasite *Plasmodium falciparum*. *Nature*. **419**:498–511.
15. Laveran, A. 1882. De la nature parasitaire de l'impaludisme. *Bull. Mem. Soc. Med. Hop. Paris*. **18**:168–176.
16. Hay, S.I., and Snow, R.W. 2006. The Malaria Atlas Project: developing global maps of malaria risk. *PLoS Med.* **3**:e473.
17. Guerra, C.A., Snow, R.W., and Hay, S.I. 2006. Mapping the global extent of malaria in 2005. *Trends Parasitol.* **22**:353–358.
18. Rowe, A.K., et al. 2006. The burden of malaria mortality among African children in the year 2000. *Int. J. Epidemiol.* **35**:691–704.
19. Desai, M., et al. 2007. Epidemiology and burden of malaria in pregnancy. *Lancet Infect. Dis.* **7**:93–104.
20. Thomson, M.C., et al. 2006. Malaria early warnings based on seasonal climate forecasts from multi-model ensembles. *Nature*. **439**:576–579.
21. Abeku, T.A., et al. 2004. Malaria epidemic early warning and detection in African highlands. *Trends Parasitol.* **20**:400–405.
22. Andrews, L., et al. 2005. Quantitative real-time polymerase chain reaction for malaria diagnosis and its use in malaria vaccine clinical trials. *Am. J. Trop. Med. Hyg.* **73**:191–198.
23. Schneider, P., et al. 2007. Submicroscopic *Plasmodium falciparum* gametocyte densities frequently result in mosquito infection. *Am. J. Trop. Med. Hyg.* **76**:470–474.
24. Drakeley, C.J., et al. 2005. Estimating medium- and long-term trends in malaria transmission by using serological markers of malaria exposure. *Proc. Natl. Acad. Sci. U. S. A.* **102**:5108–5113.
25. Moody, A. 2002. Rapid diagnostic tests for malaria parasites. *Clin. Microbiol. Rev.* **15**:66–78.
26. Jorgensen, P., Chanthap, L., Rebuena, A., Tsuyuo-ka, R., and Bell, D. 2006. Malaria rapid diagnostic tests in tropical climates: the need for a cool chain. *Am. J. Trop. Med. Hyg.* **74**:750–754.
27. Reyburn, H., et al. 2007. Rapid diagnostic tests compared with malaria microscopy for guiding outpatient treatment of febrile illness in Tanzania: randomised trial. *BMJ*. **334**:403.
28. Kwiatkowski, D.P. 2005. How malaria has affected the human genome and what human genetics can teach us about malaria. *Am. J. Hum. Genet.* **77**:171–192.
29. Reyburn, H., et al. 2005. Association of transmission intensity and age with clinical manifestations and case fatality of severe *Plasmodium falciparum* malaria. *JAMA*. **293**:1461–1470.
30. Beare, N.A., Taylor, T.E., Harding, S.P., Lewallen, S., and Molyneux, M.E. 2006. Malarial retinopathy: a newly established diagnostic sign in severe malaria. *Am. J. Trop. Med. Hyg.* **75**:790–797.
31. Maitland, K., et al. 2003. Severe *P. falciparum* malaria in Kenyan children: evidence for hypovolaemia. *OJM*. **96**:427–434.
32. Planche, T., et al. 2004. Assessment of volume depletion in children with malaria. *PLoS Med.* **1**:e18.
33. Korenromp, E.L., et al. 2005. Malaria attributable to the HIV-1 epidemic, sub-Saharan Africa. *Emerg. Infect. Dis.* **11**:1410–1419.
34. Kublin, J.G., et al. 2005. Effect of *Plasmodium falciparum* malaria on concentration of HIV-1-RNA in the blood of adults in rural Malawi: a prospective cohort study. *Lancet*. **365**:233–240.
35. Filler, S.J., et al. 2006. Randomized trial of 2-dose versus monthly sulfadoxine-pyrimethamine intermittent preventive treatment for malaria in HIV-positive and HIV-negative pregnant women in Malawi. *J. Infect. Dis.* **194**:286–293.
36. Mwangi, T.W., Bethony, J.M., and Brooker, S. 2006. Malaria and helminth interactions in humans: an epidemiological viewpoint. *Ann. Trop. Med. Parasitol.* **100**:551–570.
37. Hartgers, F.C., and Yazdanbakhsh, M. 2006. Co-infection of helminths and malaria: modulation of the immune responses to malaria. *Parasite Immunol.* **28**:497–506.
38. Berkley, J., Mwarumba, S., Bramham, K., Lowe, B., and Marsh, K. 1999. Bacteraemia complicating severe malaria in children. *Trans. R. Soc. Trop. Med. Hyg.* **93**:283–286.
39. Graham, S.M., et al. 2000. Nontyphoidal Salmonella infections of children in tropical Africa. *Pediatr. Infect. Dis. J.* **19**:1189–1196.
40. Sakata, T., and Winzler, E.A. 2007. Genomics, systems biology and drug development for infectious diseases. *Mol. Biosyst.* **3**:841–848.
41. Meissner, M., Agop-Nersesian, C., and Sullivan, W.J., Jr. 2007. Molecular tools for analysis of gene function in parasitic microorganisms. *Appl. Microbiol. Biotechnol.* **75**:963–975.
42. Eklund, E.H., and Fidock, D.A. 2007. Advances in understanding the genetic basis of antimalarial drug resistance. *Curr. Opin. Microbiol.* **10**:363–370.
43. Kooij, T.W., Janse, C.J., and Waters, A.P. 2006. *Plasmodium* post-genomics: better the bug you know? *Nat. Rev. Microbiol.* **4**:344–357.
44. Fidock, D.A., Rosenthal, P.J., Croft, S.L., Brun, R., and Nwaka, S. 2004. Antimalarial drug discovery: efficacy models for compound screening. *Nat. Rev. Drug Discov.* **3**:509–520.
45. Baird, J.K. 2005. Effectiveness of antimalarial drugs. *N. Engl. J. Med.* **352**:1565–1577.
46. Kain, K.C., Shanks, G.D., and Keystone, J.S. 2001. Malaria chemoprophylaxis in the age of drug resistance. I. Currently recommended drug regimens. *Clin. Infect. Dis.* **33**:226–234.
47. Tarun, A.S., et al. 2006. Quantitative isolation and in vivo imaging of malaria parasite liver stages. *Int. J. Parasitol.* **36**:1283–1293.
48. Sturm, A., et al. 2006. Manipulation of host hepatocytes by the malaria parasite for delivery into liver sinusoids. *Science*. **313**:1287–1290.
49. Amino, R., et al. 2006. Quantitative imaging of *Plasmodium* transmission from mosquito to



- mammal. *Nat. Med.* **12**:220–224.
50. Schultz, L.J., et al. 1994. The efficacy of antimalarial regimens containing sulfadoxine-pyrimethamine and/or chloroquine in preventing peripheral and placental *Plasmodium falciparum* infection among pregnant women in Malawi. *Am. J. Trop. Med. Hyg.* **51**:515–522.
51. Mockenhaupt, F.P., et al. 2007. Intermittent preventive treatment in infants as a means of malaria control: a randomized, double-blind, placebo-controlled trial in northern Ghana. *Antimicrob. Agents Chemother.* **51**:3273–3281.
52. Menendez, C., et al. 2007. Varying efficacy of intermittent preventive treatment for malaria in infants in two similar trials: public health implications. *Malar. J.* **6**:132.
53. Uhlemann, A.C., Yuthavong, Y., and Fidock, D. 2005. Mechanisms of antimalarial drug action and resistance. In *Molecular approaches to malaria*. I.W. Sherman, editor. ASM Press, Washington, DC, USA. 229–261.
54. Gregson, A., and Plowe, C.V. 2005. Mechanisms of resistance of malaria parasites to antifolates. *Pharmacol. Rev.* **57**:117–145.
55. Wellems, T.E., and Plowe, C.V. 2001. Chloroquine-resistant malaria. *J. Infect. Dis.* **184**:770–776.
56. Greenwood, B., and Mutabingwa, T. 2002. Malaria in 2002. *Nature.* **415**:670–672.
57. White, N.J. 2004. Antimalarial drug resistance. *J. Clin. Invest.* **113**:1084–1092.
58. Nosten, F., et al. 2000. Effects of artesunate-mefloquine combination on incidence of *Plasmodium falciparum* malaria and mefloquine resistance in western Thailand: a prospective study. *Lancet.* **356**:297–302.
59. Genovesi, R.F., Newman, D.B., Gordon, K.A., and Brewer, T.G. 1999. Acute high dose artemether toxicity in rats. *Neurotoxicology.* **20**:851–859.
60. Longo, M., et al. 2006. In vivo and in vitro investigations of the effects of the antimalarial drug dihydroartemisinin (DHA) on rat embryos. *Reprod. Toxicol.* **22**:797–810.
61. Afonso, A., et al. 2006. Malaria parasites can develop stable resistance to artemisinin but lack mutations in candidate genes *atp6* (encoding the sarcoplasmic and endoplasmic reticulum Ca²⁺ ATPase), *tctp*, *mdr1*, and *cg10*. *Antimicrob. Agents Chemother.* **50**:480–489.
62. Price, R.N., et al. 2004. Mefloquine resistance in *Plasmodium falciparum* and increased *pfmdr1* gene copy number. *Lancet.* **364**:438–447.
63. Price, R.N., et al. 2006. Molecular and pharmacological determinants of the therapeutic response to artemether-lumefantrine in multidrug-resistant *Plasmodium falciparum* malaria. *Clin. Infect. Dis.* **42**:1570–1577.
64. Basco, L.K., Le Bras, J., Rhoades, Z., and Wilson, C.M. 1995. Analysis of *pfmdr1* and drug susceptibility in fresh isolates of *Plasmodium falciparum* from sub-Saharan Africa. *Mol. Biochem. Parasitol.* **74**:157–166.
65. Hill, A.V. 2006. Pre-erythrocytic malaria vaccines: towards greater efficacy. *Nat. Rev. Immunol.* **6**:21–32.
66. Richie, T. 2006. High road, low road? Choices and challenges on the pathway to a malaria vaccine. *Parasitology.* **133**(Suppl.):S113–S144.
67. Walther, M. 2006. Advances in vaccine development against the pre-erythrocytic stage of *Plasmodium falciparum* malaria. *Expert Rev. Vaccines.* **5**:81–93.
68. Rosenberg, R., Wirtz, R.A., Schneider, I., and Burge, R. 1990. An estimation of the number of malaria sporozoites ejected by a feeding mosquito. *Trans. R. Soc. Trop. Med. Hyg.* **84**:209–212.
69. Vanderberg, J.P., and Frevort, U. 2004. Intravital microscopy demonstrating antibody-mediated immobilisation of *Plasmodium berghei* sporozoites injected into skin by mosquitoes. *Int. J. Parasitol.* **34**:991–996.
70. Kappe, S.H., Buscaglia, C.A., and Nussenzweig, V. 2004. *Plasmodium* sporozoite molecular cell biology. *Annu. Rev. Cell Dev. Biol.* **20**:29–59.
71. Sultan, A.A., et al. 1997. TRAP is necessary for gliding motility and infectivity of *Plasmodium* sporozoites. *Cell.* **90**:511–522.
72. Frevort, U., Usynin, I., Baer, K., and Klotz, C. 2006. Nomadic or sessile: can Kupffer cells function as portals for malaria sporozoites to the liver? *Cell. Microbiol.* **8**:1537–1546.
73. Ishino, T., Chinzei, Y., and Yuda, M. 2005. A *Plasmodium* sporozoite protein with a membrane attack complex domain is required for breaching the liver sinusoidal cell layer prior to hepatocyte infection. *Cell. Microbiol.* **7**:199–208.
74. Ishino, T., Yano, K., Chinzei, Y., and Yuda, M. 2004. Cell-passage activity is required for the malarial parasite to cross the liver sinusoidal cell layer. *PLoS Biol.* **2**:E4.
75. Usynin, I., Klotz, C., and Frevort, U. 2007. Malaria circumsporozoite protein inhibits the respiratory burst in Kupffer cells. *Cell. Microbiol.* **9**:2610–2628.
76. Steers, N., et al. 2005. The immune status of Kupffer cells profoundly influences their responses to infectious *Plasmodium berghei* sporozoites. *Eur. J. Immunol.* **35**:2335–2346.
77. Frevort, U., et al. 2005. Intravital observation of *Plasmodium berghei* sporozoite infection of the liver. *PLoS Biol.* **3**:e192.
78. Mikolajczak, S.A., and Kappe, S.H. 2006. A clash to conquer: the malaria parasite liver infection. *Mol. Microbiol.* **62**:1499–1506.
79. Labaied, M., et al. 2007. *Plasmodium yoelii* sporozoites with simultaneous deletion of P52 and P36 are completely attenuated and confer sterile immunity against infection. *Infect. Immun.* **75**:3758–3768.
80. Mikolajczak, S.A., Jacobs-Lorena, V., MacKellar, D.C., Camargo, N., and Kappe, S.H. 2007. L-FABP is a critical host factor for successful malaria liver stage development. *Int. J. Parasitol.* **37**:483–489.
81. Mueller, A.K., et al. 2005. *Plasmodium* liver stage developmental arrest by depletion of a protein at the parasite-host interface. *Proc. Natl. Acad. Sci. U. S. A.* **102**:3022–3027.
82. Mueller, A.K., Labaied, M., Kappe, S.H., and Matuschewski, K. 2005. Genetically modified *Plasmodium* parasites as a protective experimental malaria vaccine. *Nature.* **433**:164–167.
83. Tarun, A.S., et al. 2007. Protracted sterile protection with *Plasmodium yoelii* pre-erythrocytic genetically attenuated parasite malaria vaccines is independent of significant liver-stage persistence and is mediated by CD8⁺ T cells. *J. Infect. Dis.* **196**:608–616.
84. Nussenzweig, R.S., Vanderberg, J., Most, H., and Orton, C. 1967. Protective immunity produced by the injection of x-irradiated sporozoites of *Plasmodium berghei*. *Nature.* **216**:160–162.
85. Clyde, D.F. 1975. Immunization of man against *falciparum* and *vivax* malaria by use of attenuated sporozoites. *Am. J. Trop. Med. Hyg.* **24**:397–401.
86. Mueller, A.K., et al. 2007. Genetically attenuated *Plasmodium berghei* liver stages persist and elicit sterile protection primarily via CD8⁺ T cells. *Am. J. Pathol.* **171**:107–115.
87. Jobe, O., et al. 2007. Genetically attenuated *Plasmodium berghei* liver stages induce sterile protracted protection that is mediated by major histocompatibility complex Class I-dependent interferon-gamma-producing CD8⁺ T cells. *J. Infect. Dis.* **196**:599–607.
88. Doolan, D.L., and Hoffman, S.L. 2000. The complexity of protective immunity against liver-stage malaria. *J. Immunol.* **165**:1453–1462.
89. Stoute, J.A., et al. 1997. A preliminary evaluation of a recombinant circumsporozoite protein vaccine against *Plasmodium falciparum* malaria. RTS,S Malaria Vaccine Evaluation Group. *N. Engl. J. Med.* **336**:86–91.
90. Kester, K.E., et al. 2001. Efficacy of recombinant circumsporozoite protein vaccine regimens against experimental *Plasmodium falciparum* malaria. *J. Infect. Dis.* **183**:640–647.
91. Bojang, K.A., et al. 2001. Efficacy of RTS,S/AS02 malaria vaccine against *Plasmodium falciparum* infection in semi-immune adult men in The Gambia: a randomised trial. *Lancet.* **358**:1927–1934.
92. Alonso, P.L., et al. 2004. Efficacy of the RTS,S/AS02A vaccine against *Plasmodium falciparum* infection and disease in young African children: randomised controlled trial. *Lancet.* **364**:1411–1420.
93. Aponte, J.J., et al. 2007. Safety of the RTS,S/AS02D candidate malaria vaccine in infants living in a highly endemic area of Mozambique: a double blind randomised controlled phase I/IIb trial. *Lancet.* **370**:1543–1551.
94. Alonso, P.L., et al. 2005. Duration of protection with RTS,S/AS02A malaria vaccine in prevention of *Plasmodium falciparum* disease in Mozambican children: single-blind extended follow-up of a randomised controlled trial. *Lancet.* **366**:2012–2018.
95. Kester, K.E., et al. 2007. A phase I/IIa safety, immunogenicity, and efficacy bridging randomized study of a two-dose regimen of liquid and lyophilized formulations of the candidate malaria vaccine RTS,S/AS02A in malaria-naive adults. *Vaccine.* **25**:5359–5366.
96. Cohen, S., McGregor, I.A., and Carrington, S. 1961. Gamma-globulin and acquired immunity to human malaria. *Nature.* **192**:733–737.
97. Gupta, S., Snow, R.W., Donnelly, C.A., Marsh, K., and Newbold, C. 1999. Immunity to non-cerebral severe malaria is acquired after one or two infections. *Nat. Med.* **5**:340–343.
98. Miller, L.H., Mason, S.J., Clyde, D.F., and McGinniss, M.H. 1976. The resistance factor to *Plasmodium vivax* in blacks. The Duffy-blood-group genotype, FyFy. *N. Engl. J. Med.* **295**:302–304.
99. Devi, Y.S., et al. 2007. Immunogenicity of *Plasmodium vivax* combination subunit vaccine formulated with human compatible adjuvants in mice. *Vaccine.* **25**:5166–5174.
100. Baum, J., Maier, A.G., Good, R.T., Simpson, K.M., and Cowman, A.F. 2005. Invasion by *P. falciparum* merozoites suggests a hierarchy of molecular interactions. *PLoS Pathog.* **1**:e37.
101. Fried, M., and Duffy, P.E. 1996. Adherence of *Plasmodium falciparum* to chondroitin sulfate A in the human placenta. *Science.* **272**:1502–1504.
102. Fried, M., Nosten, F., Brockman, A., Brabin, B.J., and Duffy, P.E. 1998. Maternal antibodies block malaria. *Nature.* **395**:851–852.
103. Francis, S.E., et al. 2007. Six genes are preferentially transcribed by the circulating and sequestered forms of *Plasmodium falciparum* parasites that infect pregnant women. *Infect. Immun.* **75**:4838–4850.
104. Salanti, A., et al. 2003. Selective upregulation of a single distinctly structured var gene in chondroitin sulphate A-adhering *Plasmodium falciparum* involved in pregnancy-associated malaria. *Mol. Microbiol.* **49**:179–191.
105. Viebig, N.K., et al. 2005. A single member of the *Plasmodium falciparum* var multigene family determines cytoadhesion to the placental receptor chondroitin sulphate A. *EMBO Rep.* **6**:775–781.
106. Gamain, B., et al. 2005. Identification of multiple chondroitin sulfate A (CSA)-binding domains in the var2CSA gene transcribed in CSA-binding parasites. *J. Infect. Dis.* **191**:1010–1013.
107. Duffy, P.E. 2007. *Plasmodium* in the placenta: parasites, parity, protection, prevention and possibly preclampsia. *Parasitology.* **134**:1877–1881.
108. Schofield, L., et al. 1993. Neutralizing monoclonal antibodies to glycosylphosphatidylinositol, the dominant TNF-alpha-inducing toxin of *Plasmodium falciparum*: prospects for the immunotherapy of



- severe malaria. *Ann. Trop. Med. Parasitol.* **87**:617–626.
109. Naik, R.S., et al. 2000. Glycosylphosphatidylinositol anchors of *Plasmodium falciparum*: molecular characterization and naturally elicited antibody response that may provide immunity to malaria pathogenesis. *J. Exp. Med.* **192**:1563–1576.
110. Schofield, L., Hewitt, M.C., Evans, K., Siomos, M.A., and Seeberger, P.H. 2002. Synthetic GPI as a candidate anti-toxic vaccine in a model of malaria. *Nature.* **418**:785–789.
111. Perraut, R., et al. 2005. Differential antibody responses to *Plasmodium falciparum* glycosylphosphatidylinositol anchors in patients with cerebral and mild malaria. *Microbes Infect.* **7**:682–687.
112. de Souza, J.B., et al. 2002. Prevalence and boosting of antibodies to *Plasmodium falciparum* glycosylphosphatidylinositols and evaluation of their association with protection from mild and severe clinical malaria. *Infect. Immun.* **70**:5045–5051.
113. Carter, R. 2001. Transmission blocking malaria vaccines. *Vaccine.* **19**:2309–2314.
114. Fegan, G.W., Noor, A.M., Akhwale, W.S., Cousens, S., and Snow, R.W. 2007. Effect of expanded insecticide-treated bednet coverage on child survival in rural Kenya: a longitudinal study. *Lancet.* **370**:1035–1039.
115. D'Alessandro, U., et al. 1995. Mortality and morbidity from malaria in Gambian children after introduction of an impregnated bednet programme. *Lancet.* **345**:479–483.
116. Schellenberg, J.R., et al. 2001. Effect of large-scale social marketing of insecticide-treated nets on child survival in rural Tanzania. *Lancet.* **357**:1241–1247.
117. Hargreaves, K., et al. 2000. *Anopheles funestus* resistant to pyrethroid insecticides in South Africa. *Med. Vet. Entomol.* **14**:181–189.
118. Brooke, B.D., et al. 2001. Bioassay and biochemical analyses of insecticide resistance in southern African *Anopheles funestus* (Diptera: Culicidae). *Bull. Entomol. Res.* **91**:265–272.
119. Casimiro, S., Coleman, M., Mohloai, P., Hemingway, J., and Sharp, B. 2006. Insecticide resistance in *Anopheles funestus* (Diptera: Culicidae) from Mozambique. *J. Med. Entomol.* **43**:267–275.
120. N'Guessan, R., Corbel, V., Akogbeto, M., and Rowland, M. 2007. Reduced efficacy of insecticide-treated nets and indoor residual spraying for malaria control in pyrethroid resistance area, Benin. *Emerg. Infect. Dis.* **13**:199–206.
121. Girod, R., Orlandi-Pradines, E., Rogier, C., and Pages, F. 2006. Malaria transmission and insecticide resistance of *Anopheles gambiae* (Diptera: Culicidae) in the French military camp of Port-Bouet, Abidjan (Cote d'Ivoire): implications for vector control. *J. Med. Entomol.* **43**:1082–1087.
122. Tripet, F., et al. 2007. Longitudinal survey of knockdown resistance to pyrethroid (kdr) in Mali, West Africa, and evidence of its emergence in the Bamaiko form of *Anopheles gambiae* s.s. *Am. J. Trop. Med. Hyg.* **76**:81–87.
123. Martinez-Torres, D., et al. 1998. Molecular characterization of pyrethroid knockdown resistance (kdr) in the major malaria vector *Anopheles gambiae* s.s. *Insect Mol. Biol.* **7**:179–184.
124. Kwon, H.W., Lu, T., Rutzler, M., and Zwiebel, L.J. 2006. Olfactory responses in a gustatory organ of the malaria vector mosquito *Anopheles gambiae*. *Proc. Natl. Acad. Sci. U. S. A.* **103**:13526–13531.
125. Zwiebel, L.J., and Takken, W. 2004. Olfactory regulation of mosquito-host interactions. *Insect Biochem. Mol. Biol.* **34**:645–652.
126. Dinglasan, R.R., et al. 2007. Disruption of *Plasmodium falciparum* development by antibodies against a conserved mosquito midgut antigen. *Proc. Natl. Acad. Sci. U. S. A.* **104**:13461–13466.
127. Marrelli, M.T., Li, C., Rasgon, J.L., and Jacobs-Lorena, M. 2007. Transgenic malaria-resistant mosquitoes have a fitness advantage when feeding on *Plasmodium*-infected blood. *Proc. Natl. Acad. Sci. U. S. A.* **104**:5580–5583.
128. Windbichler, N., et al. 2007. Homing endonuclease mediated gene targeting in *Anopheles gambiae* cells and embryos. *Nucleic Acids Res.* **35**:5922–5933.
129. Chen, C.H., et al. 2007. A synthetic maternal-effect selfish genetic element drives population replacement in *Drosophila*. *Science.* **316**:597–600.
130. Holt, R.A., et al. 2002. The genome sequence of the malaria mosquito *Anopheles gambiae*. *Science.* **298**:129–149.
131. Nene, V., et al. 2007. Genome sequence of *Aedes aegypti*, a major arbovirus vector. *Science.* **316**:1718–1723.
132. Noedl, H. 2005. Artemisinin resistance: how can we find it? *Trends Parasitol.* **21**:404–405.